Jasper Therapeutics
JSPR
24 hedge funds and large institutions have $69.6M invested in Jasper Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
1,569% more call options, than puts
Call options by funds: $801K | Put options by funds: $48K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.23% less ownership
Funds ownership: 5.72% → 5.49% (-0.23%)
4% less funds holding
Funds holding: 25 → 24 (-1)
57% less capital invested
Capital invested by funds: $161M → $69.6M (-$91.1M)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.04M |
| 2 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$147K |
| 3 |
BC
BIT Capital
Berlin,
Germany
|
+$135K |
| 4 |
State Street
Boston,
Massachusetts
|
+$98K |
| 5 |
Renaissance Technologies
New York
|
+$49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.3M |
| 2 |
Morgan Stanley
New York
|
-$1.33M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$232K |
| 4 |
VF
Virtu Financial
New York
|
-$163K |
| 5 |
Millennium Management
New York
|
-$156K |
JSPR Hedge Fund Activity: Q1 2022 in Review
24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2022, worth a combined $69.6M — down 57% from $161M a quarter earlier.
Fund positioning in JSPR was balanced in Q1 2022: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 7 trimmed.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $3.04M. The largest seller was Federated Hermes, cutting an estimated $4.3M.
- 24 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $69.6M of Jasper Therapeutics stock for Q1 2022, down 57% quarter-over-quarter.
- 6 funds opened new Jasper Therapeutics positions in Q1 2022 and 6 closed out, a net change of 0 holders.
- The largest Jasper Therapeutics buyer in Q1 2022 was Sectoral Asset Management, an estimated $3.04M added.
- The largest Jasper Therapeutics seller in Q1 2022 was Federated Hermes, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2022.